POLO D'INNOVAZIONE DI GENOMICA, GENETICA E BIOLOGIA SRL

Their core work

POLOGGB is a Siena-based private genomics and genetics SME that provides specialized life science research services across multiple biological domains. Their work spans population health monitoring (vaccine immunity surveillance), plant reproductive biology, vector-borne disease research infrastructure, and chemical hazard assessment using advanced omics and New Approach Methodologies. They function as a genomics service provider embedded in large international research consortia, contributing molecular biology and genetic analysis capabilities to projects that require these competencies.

What they specialise in

How they've shifted over time

POLOGGB's early H2020 work (2015-2019) was broad and exploratory, spanning vaccine surveillance and plant reproduction genetics — two quite different biological domains connected only by underlying genomics expertise. From 2017 onward, their focus sharpened toward applied health and environmental biology: first vector-borne diseases (INFRAVEC2) and then chemical toxicology using advanced omics methods (SCENARIOS, starting 2021). The trajectory shows a clear shift from fundamental biology toward health-relevant applied genomics with growing emphasis on regulatory science and environmental health.

POLOGGB is moving toward regulatory-relevant omics applications — chemical safety assessment and NAM/IATA frameworks — positioning them for the growing EU push to replace animal testing with molecular approaches.

How they like to work

POLOGGB operates exclusively as a consortium participant, never leading projects, which is typical for a specialized SME contributing specific technical capabilities to larger efforts. With 48 unique partners across 23 countries from just 4 projects, they work in large, diverse consortia — their average consortium has around 12+ partners. This pattern suggests they are a reliable specialist contributor that larger coordinators bring in for genomics and molecular biology expertise.

Despite only 4 projects, POLOGGB has built a remarkably wide network of 48 partners across 23 countries, reflecting participation in large pan-European consortia. Their reach extends well beyond Italy across most of the EU and likely includes African and Asian partners through the vector-borne disease work.

What sets them apart

POLOGGB occupies an unusual niche: a small private genomics company that bridges multiple biological domains — from insect vectors to plant genetics to chemical toxicology — through a common thread of molecular profiling and omics. Their Siena location places them near major Italian biomedical research institutions. For consortium builders, they offer flexible genomics capacity without the overhead of a large university partner, and their breadth means they can contribute meaningfully to projects spanning health, agriculture, and environmental safety.

Highlights from their portfolio

• INFRAVEC2
  Their largest project by far (EUR 960K), building shared research infrastructure for vector-borne disease control — covering mosquitoes, sandflies, and tsetse flies across multiple deadly diseases.
• SCENARIOS
  Their most recent and forward-looking project, applying New Approach Methodologies and omics to PFAS hazard assessment — a topic of intense regulatory interest across Europe.
• Vaccinesurvey
  Demonstrates their population health monitoring capability, tracking vaccine immunity at scale — relevant expertise that proved prescient given post-2020 vaccine surveillance needs.